Literature DB >> 32898558

Acetylcholinesterase inhibitors (nerve agents) as weapons of mass destruction: History, mechanisms of action, and medical countermeasures.

Vassiliki Aroniadou-Anderjaska1, James P Apland2, Taiza H Figueiredo3, Marcio De Araujo Furtado4, Maria F Braga5.   

Abstract

Nerve agents are organophosphorus acetylcholinesterase inhibitors. Acute exposure to nerve agents can cause rapid death. In this review, we summarize the history of nerve agent development and use in warfare, the mechanisms by which these agents cause death or long-term brain damage, and the treatments for preventing death or long-term morbidity. The G-series nerve agents, tabun, sarin, soman, ethyl sarin, and cyclosarin, were developed by the Nazis. VX, the best-known of the V-series agents, was synthesized in the 1950's by a British scientist. Little is known about the development of the novichoks (the "A-series") by the former Soviet Union. Nerve agents were used for the first time in the battlefield by the Iraqi government in the Iran-Iraq War, in the 1980s. The Chemical Weapons Convention, in 1993, banned all chemical weapons production and use, yet, sarin was subsequently used in terrorist attacks in Japan and, recently, in the war in Syria. Pyridostigmine has been used as a prophylactic treatment, and bioscavengers are presently investigated as a better alternative. Atropine, along with an oxime, can prevent rapid death from the nerve agent-induced peripheral cholinergic crisis. Treatment with diazepam or midazolam for the cessation of nerve agent-induced status epilepticus cannot protect against brain damage, and, therefore, these benzodiazepines should be replaced by novel anticonvulsants and neuroprotectants. The AMPA/GluK1 receptor antagonist LY293558 (tezampanel) has shown superior antiseizure and neuroprotective efficacy against soman, particularly when administered in combination with caramiphen, an antagonist of muscarinic and NMDA receptors. This article is part of the special issue entitled 'Acetylcholinesterase Inhibitors: From Bench to Bedside to Battlefield'.
Copyright © 2020. Published by Elsevier Ltd.

Entities:  

Keywords:  Caramiphen; Diazepam; LY293558; Midazolam; Nerve agents; Status epilepticus

Year:  2020        PMID: 32898558     DOI: 10.1016/j.neuropharm.2020.108298

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  4 in total

1.  Dual Use of Artificial Intelligence-powered Drug Discovery.

Authors:  Fabio Urbina; Filippa Lentzos; Cédric Invernizzi; Sean Ekins
Journal:  Nat Mach Intell       Date:  2022-03-07

2.  Comparative profile of refractory status epilepticus models following exposure of cholinergic agents pilocarpine, DFP, and soman.

Authors:  Doodipala Samba Reddy; Marcus Zaayman; Ramkumar Kuruba; Xin Wu
Journal:  Neuropharmacology       Date:  2021-04-18       Impact factor: 5.273

3.  Antiseizure and Neuroprotective Efficacy of Midazolam in Comparison with Tezampanel (LY293558) against Soman-Induced Status Epilepticus.

Authors:  Taiza H Figueiredo; Vassiliki Aroniadou-Anderjaska; Volodymyr I Pidoplichko; James P Apland; Maria F M Braga
Journal:  Toxics       Date:  2022-07-22

Review 4.  Counteracting poisoning with chemical warfare nerve agents.

Authors:  Nikolina Maček Hrvat; Zrinka Kovarik
Journal:  Arh Hig Rada Toksikol       Date:  2020-12-31       Impact factor: 2.078

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.